MicroPort CardioFlow Medtech Corporation
微创心通医疗科技有限公司

2024 Annual Results Presentation

April 2025

Disclaimer

This presentation was prepared by MicroPort CardioFlow Medtech Corporation (微创心通医疗科技有限公司) (the "Company") solely for use at the presentation for 2024 annual results releasing.

The information contained in this presentation has not been reviewed by any regulatory authority in any jurisdiction nor independently verified. No representation or warranty, expressed or implied, is made and no reliance should be placed on the accuracy, fairness or completeness of the information contained herein. The information and opinions contained in this presentation are provided as of the date of this presentation or the respective cut-off date in respect of the clinical trial data, are subject to change without notice and will not be updated or otherwise revised to reflect any developments, which may occur after the date of the presentation. Neither the Company nor any of its affiliates, advisers or representatives accepts any liability whatsoever for any actual or consequential loss or damages howsoever arising from the provision or use of any information contained in this presentation. The Company may alter, modify or otherwise change in any manner the contents of this presentation, without obligation to notify any person of such alternations, modifications or changes.

This presentation contains statements that constitute forward-looking statements. These statements can be recognized by the use of words such as "expects", "plan", "will", "estimates", "projects", "intends", or words of similar meaning or intent. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions. The Company has no obligation and does not undertake to revise forward- looking statements contained in this presentation to reflect future events or circumstances. Accordingly, you should not place undue reliance on any forward-looking information.

This presentation is for information purposes only and does not constitute or form part of, and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company, any of its holding companies, or any of its subsidiaries in any jurisdiction or an inducement to enter into investment activity. No part of this presentation, nor the fact of its distribution, shall form the basis of or be relied upon in connection with any contract, commitment or investment decision whatsoever. Any decision to purchase or subscribe for any securities of the Company should be made after seeking appropriate professional advice. By attending or receiving this presentation you acknowledge that you will be solely responsible for your own assessment of the business, the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

This document does not constitute a prospectus or an offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance of Hong Kong and may only be made available to professional investors within the meaning of the Securities and Futures Ordinance of Hong Kong. The receipt of this document by any recipient is not to be taken as constituting the receipt of investment advice or an establishment of customer or client relationship.

Agenda

Business Highlights

A Glance of Year 2024

Healthy and Sustainable Development, Continuous Global Expansion

Healthy and high-quality growth

Significant loss reduction attributed to improvement of operating efficiency

MicroPort 心通医疗

To provide trustworthy and universal access to state-of-the-art total solutions to treat structural heart diseases

Sustained enrichment of Structural Heart Portfolio with flagship products

Expanded and deepening global footprint

Business Highlights

Revenue (RMB)	362 mn	↑ 8% YoY
GPM	70.3%	↑ 1.1ppts
Commercial Profitability	24%	↑ 22ppts
LAAC Implantations[1]	400+	37% average monthly growth rate[2]
Overseas Revenue (RMB)	23.6 mn	↑ 108% YoY
OPEX Ratio	104%	↓ 54ppts
Net Loss (RMB)	53.3 mn	↓ 89% YoY

1. As of the releasing day of this report
2. Average monthly growth rate of implantations since the commercialization of AnchorMan® LAAC from March 2024 to March 2025

Enrichment of Structural Heart Portfolio

- **2 new NMPA Approval:** VitaFlow Liberty® Flex; AnchorMan® LAAC
- **3 new CE Marks:** VitaFlow Liberty®; AnchorMan® LAAC & LAAA
- **Emerging Market Registrations:** VitaFlow Liberty® in 18 countries/regions[1]; Alwide® Plus in 10 countries
- **FIM Study:** Self-developed TMVR product 20+ human applications
- **Pivotal Study:** AltaValve™
  - Granted two Breakthrough Device Designations by the FDA
  - Conducted pivotal clinical study in Europe and the US
- **6 in Design:** VitaFlow® IV \ AR product \ 2 TTV products \ New Gen. LAAC & LAAA

Overseas TAVI Implantations



LAAC Implantations Trend



Total Solutions

Synergized Market Strategy and Operation Optimization Propelled Sustainable Growth

China TAVI: Resilient Client Base & Optimized Efficiency



Sales Manpower Efficiency[2]



TAVI Implantations per Salesperson



Note:

1. *Our sales & marketing team divide covered hospitals into 3 tiers based on their estimated total TAVI implantation volume in 2024 : 1) top 20 centers (top centers); 2) top 21-100 centers (fast-growing centers); and 3) centers that fall below top 100 (high-potential centers).*
2. *Sales manpower efficiency equals to revenue (in million RMB) divided by the average number of sales personnel of the year;*
3. *As of the releasing day of this report*
4. *Physicians who can perform surgeries with our products independently*

Overseas TAVI： Rapid Expansion

Countries Coverage	~20
Implantations[3]	300+
Hospital Coverage[3]	~100
Independent Physicians[4]	~50

LAAC： Robust Growth

Provinces Coverage[3]	15
Implantations[3]	400+
Hospital Coverage[3]	~60
Independent Physicians[4]	~50

Intensified Brand Building and Comprehensive Market Cultivation

Differentiated Market Positioning Strategy to Drive Implantation Increment

- To shift clients' focus from short-term to long-term clinical results, highlighted VitaFlow® 's positioning as ***the first valve choice under full lifecycle considerations*** and ***the most trustworthy self-expanding TAVI brand*** serving as the key strategic direction for AS promotion, which have gained extensive clients endorsement and incremental implantations
- Through **40+** strategic FAB publicities, directly engaged **1,500+ person-time clients**, with **100+** brand exposures, and cultivated **200+ new advocates**

Carve Out A Unique Position within Global Market

- **Europe-** Participated in well-known international academic conferences such as EuroPCR & Coronary and Structural Course and London Valves, attracted numerous European experts and further increased the influence of CardioFLow brand
- **South America- ~10%** market share was achieved In Argentine with 85+ implantations, despite the rapidly evolving competitive landscape
- **Asia-** Registered in **8** Asian countries in 2024, with the completion of multiple first-time implantations such as in Indonesia and Azerbaijan

Seize the Golden Opportunity for LAAC Launch

- **Customized promotion activities with regional top center to influence the peripheral centers**: Launched the LAAC training initiative in The First Affiliated Hospital of Ningbo University, in which our LAAC product ranks No. 1 in implantation volume, garnering widespread acclaim from clients, and lead to **implantations** by experts of other hospitals participating the training
- **Collaborate with electrophysiology manufacturers** to promote the "catheter ablation +LAAC" one-stop procedure, which accounts for over half of our LAAC implantations
- **Leveraging diverse innovative digital marketing methods**: Developing a LAAC online academic resource library, created LAAC module on CFI Structural Heart Channel, gained **50,000+** browsing times

Ongoing Commitment to Global Registrations and Vigorous Expansion

VitaFlow Liberty®

2021	China
	Argentina
2022	Brazil
	Colombia
2023	Thailand
	Russia
	Indonesia
2024	**Hong Kong SAR**
	CE
	Saudi Arabia
	Serbia
	Malaysia
	Belarus
	Iran
	Korea
	Turkey
	India

VitaFlow Liberty ® Flex

2024	**China**

AnchorMan® LAAC&LAAA

2024	**China**
2025	**CE**

Alwide® Plus

2021	China	2023	Thailand	**2024**	**Mexico**
2022	Argentina		Russia		
	Colombia		Indonesia		
	Brazil		Hong Kong		
			Saudi Arabia		

Product Pipeline Update

Innovative and High-quality Total Solutions for Structural Heart Diseases

All-round Structural Heart Portfolio via In-House R&D and Collaboration with Global Partners

3 launched
2 under R&D



TAVI

- VitaFlow ® and VitaFlow Liberty® were widely used with positive results both in clinical trials and real world
- VitaFlow Liberty® Flex received NMPA approval in December 2024
- VitaFlow®IV and AR product in design stage

2 launched
2 under R&D

Left Atrial Appendage Products

- AnchorMan® LAAC and LAAA System received NMPA approval and CE mark *
- Completed 400+ domestic implantations and gained positive feedback*
- Next generation LAAC and LAAA under R&D

* As of l the releasing day of this report

2 under R&D

TMV

- Inhouse R&D + Collaboration with global partner 4C Medical
- Successful FIM of self-developed TMVR product with positive 1-year follow up, marking the world's first dry-tissue TMVR system with clinical application

2 under R&D

TTV

- 2 replacement products under R&D
- Inhouse R&D + Collaboration with global partner 4C Medical

2 launched[1]

1 of which in CE registration progress

Procedural Accessories

- Alwide® Plus balloon catheter successfully registered in 10 countries including Argentina, Colombia and Russia and CE registration in progress
- AccuSniper™ Double-Layer Balloon Catheter received NMPA approval

VitaFlow® Series: Positive Clinical Results Thanks to Advantageous Features

VitaFlow®



Relatively lower all-cause mortality rate and major (disabling) stroke

1-year follow-up period

0 moderate or severe PVL

5-year follow-up period

81.8% patient survival rate

2-year follow-up period

0 major (disabling) stroke

8-year follow-up period

60.9% patient survival rate

All-Cause Mortality Comparison with Peers

Time	VitaFlow®	Peer I (China)	Peer II (U.S.)
1-year	**2.7%**	5.9%	14.2%
2-year	**4.5%**	11.6%	22.2%
3-year	**10.9%**	17.4%	32.9%
4-year	**12.7%**	26.7%	N/A
5-year	**18.2%**	34.1%	55.3%
6-year	**24.8%**	38.2%	N/A
7-year	**31.4%**	47.73%	N/A
8-year	**39.1%**	56.98%	N/A

VitaFlow Liberty®



the world's only commercialized motorized retrievable TAVI system

Significantly reduced intraoperative valve-in-valve incidence during the procedure

Product	VIV Incidence
VitaFlow Liberty®	**4.3%** (7/163)
VitaFlow®	8.2% (9/110)

Note: Please refer to Appendix 2 for full clinical data comparison.

100% retrieval success

30-day follow-up period

0 major (disabling) stroke

Received CE Mark, and successfully registered in 18 countries/regions*

**As of the releasing day of this report*

VitaFlow Liberty® Flex



Steerable catheter significantly improve patient outcomes, and won strong KOL endorsements

- Inherit all the advantages of VitaFlow Liberty® , provide physicians with excellent ease-of-use and further improve procedure efficiency and release accuracy
- **The world's only** true coaxial steering self-expanding TAVI delivery system
- **100% intraoperative success** in dozens of commercial cases completed, with no device-related failures reported

Received NMPA approval on 16 December, 2024

AnchorMan® LAAC and LAAA: Brilliant Clinical Results

AnchorMan® Left Atrial Appendage Closure System

12-month outcomes of the randomized controlled trial of the AnchorMan® LAAC



Safety

98.1% Clinical success rate for both AnchorMan® and WatchMan® LAAC group

Effectiveness

100% LAAC Occlusion rate for both AnchorMan® and WatchMan® LAAC group

Superiority

94.3% vs **84.1%** Excellent performance of no leak(<3mm) AnchorMan® to WatchMan® device at 12 mon.

Received NMPA approval on January 5, 2024 **Received CE mark in February 2025**

The only domestic semi-closed structure LAAC System certified by both CE and NMPA

- Semi-closed structure formed by the "3D folding" technology , Rounded and soft distal end:
  - combines the merits of an open and closed closure device
  - reduces damage to the LAA tissue
  - stable anchoring
- Dense NiTi alloy frame design: achieves better sealing performance
- Two deployment models: advancement and unsheathe, easier operation

AnchorMan® Left Atrial Appendage Access System

- Compatible with AnchorMan® LAAC, providing the femoral venous and trans-atrial septal access
- Two sizes: single curve and double curve
- The access sheath outer diameter is 14 Fr

Received NMPA approval in October 2023 **Received CE mark in 2024**

Self-developed TMVR Product: FIM Study Confirming Safety and Efficacy

TMVR pain points: anchoring difficulty, LVOTO risk, LV function impairment, long learning curve…

- **World's first dry-tissue TMVR system with clinical application**
- **Dry tissue for better biocompatibility and anti-calcification properties**
- **Compatible with both trans-septal or trans-apical approaches**



- **Low profile of stent design reducing LVOTO (Left Ventricular Outflow Tract obstruction) risks**
- **Completed 20+ CU implantations, with the longest 2-year follow-up, delivering excellent MR reduction results**
- **Ease-of-use and accurate positioning, device time is only 15-25 mins**

AltaValve™: Received Breakthrough and IDE Approval of FDA

TMVR pain points: anchoring difficulty, LVOTO risk, LV function impairment, long learning curve…

Product Features

- Atrial fixation minimizes the risk of LVOT
- Supra-annular design with minimal interaction with LV, preserving its structure
- Fully recapturable implant prior to final release
- Allows treatment of broad patient population covering both DMR and FMR



Progress and Milestones

- Granted two breakthrough device designations by the FDA for the treatment of
  - (a) moderate-to-severe or severe MR, and
  - (b) moderate-to-severe or severe MR with moderate/severe mitral annular calcification
- Conducted pivotal clinical study based on the IDE by the FDA in **Europe and the United States**
- Obtained a $175 million financing led by Boston Scientific Corporation

Innovation Intensified New Gen. Pipelines

TAVI

VitaFlow ® IV

Transcatheter Aortic Valve Implantation System



- Inherit the technical features of this series
- focus on enhancing safety, effectiveness, and usability
- **In R&D and design stage**

AR product

In-house Development

- Low oversize and low implantation depth reduce pacemaker
- Commissure alignment to facilitates coronary artery treatment
- Dry tissue for better biocompatibility and anti-calcification properties
- **In R&D and design stage**

LAAC & LAAA

AnchorMan®

New Gen. LAAC & LAAA

- Improve recovery performance and reduce payout rates
- Cover larger left atrial appendage
- Reduce procedure difficulty and avoid re-perforation of the septum
- Reduce the risk of device thrombosis
- Reduce or even avoid the use of postoperative anticoagulants
- **In R&D and design stage**

TTV

TTV product

In-house Development

- Minimized postoperative complications due to oversizing by reducing radial support.
- Effective control of postoperative tricuspid regurgitation
- Simplified operation of the delivery system, with better ease of use and low learning curve
- **In R&D and design stage**

TTV product

Partnership with 4C (in R&D)

Financial Review

Rapid Revenue Growth Coupled by Increase in Gross Profit

Net Loss (RMB'000)



Revenue (RMB'000)



Gross Profit (RMB'000) & **Gross Profit Margin**



- **Net Loss** sharply Narrowed by 88.7% in 2024; Operating Loss Narrowed by 67.0%
- **Overall revenue** increased by 7.5% in 2024, driven by global commercialization and revenue contribution from new product LAAC
- **Overseas revenue contribution** reached RMB23.58 mn in 2024
- **GPM** further improved by 1.1 ppts in 2024 thanks to our strengthened bargaining power, domestic sourcing, improved production yield rate and manufacturing efficiency

Effective Cost Control to achieve healthy and sustainable growth

Co-ordinate internal and external resources, enhancing operational efficiency, and driving the business to achieve healthy and sustainable growth.

Our operational expenses[1] vs revenue ratio decreased by 53.8 percent points from 157.8% in 2023 to 104.0% in 2024.

Distribution Expenses (RMB'000)

% of revenue

66.3% → 45.6%

- Due to the effort to strengthen the synergies and interconnections of sales channels while expanding our sales, and enhancing operational efficiency



R&D Expenses (RMB'000)

% of revenue

70.6% → 42.4%

- Based on the market outlook and input-output efficiency, evaluated and adjusted the priority and resource input in a prudent manner



Administrative Expenses (RMB'000)

% of revenue

20.9% → 15.9%

- Due to the stringent control and reduction of administrative expenses to further enhance the operational efficiency



1. *Refers to the total amount of research and development, distribution and administrative expenses as percentage of revenue.*

Sufficient Cash Reserve for Future Development

Cash Outflow from Operating Activities

(RMB'000)



Cash and Cash Equivalents*

(RMB'000)



We maintained sufficient cash balance as of 31, Dec 2024 of RMB1.36 billion*, which can support us to strengthen our product pipelines, to improve our production capacity and further commercialization, till break-even.

*Including pledged and time deposits

Appendix

Appendix 1: Overview of Product Pipeline

		Product	Pre-clinical	Clinical trial	Registration
Aortic valve products	VitaFlow® System	VitaFlow®	Launched		
			Successfully registered in Argentina and Thailand		
		Alwide® balloon catheter*	Launched		
			Successfully registered in Argentina and Thailand		
	VitaFlow Liberty® System	VitaFlow Liberty® *(Retrievable)*	Launched		
			★ Successfully registered in 16 countries/regions including EU, Argentina, India and Russia		
			★ Registration in emerging markets in progress		
		Angelguide® tip-preshaped super stiff guidewire*	Launched		
			Successfully registered in Argentina, Colombia, and Brazil		
	VitaFlow Liberty® Flex *(Steerable delivery system)* ★		Launched		
	VitaFlow® IV *(Lower profile, better durability and hydrodynamic properties)* ★		Design stage		
	Self- developed AR product ★		Design stage		
Mitral valve products	Self-developed replacement product ★		FIM Study		
	AltaValve™ – Replacement product ★		FIM Study		
	(Partnership with 4C Medical – commercialization rights in China) ★		Pivotal IDE study in progress		
Tricuspid valve products	Self-developed replacement product ★		Design stage		
	Replacement product *(Partnership with 4C Medical)* ★		Design stage		
Procedural accessories	Alwide® Plus balloon catheter		Launched		
	★		Successfully registered in 10 countries including Argentina, Colombia and Russia		
	★		CE Marking registration and registration in emerging markets in progress		
	AccuSniper™ double-layer balloon catheter		Launched		
Left Atrial Appendage products	AnchorMan® Left Atrial Appendage Closure System		Launched		
	★		Received CE mark		
	AnchorMan® Left Atrial Appendage Access System ★		Launched		
	★		Received CE mark		
	New Gen. AnchorMan® Left Atrial Appendage Closure System ★		Design stage		
	New Gen. AnchorMan® Left Atrial Appendage Access System (steerable) ★		Design stage		

China status Global status

★ Major Progress during the Reporting Period

* These procedural accessories are registered and commercialized offered as part of VitaFlow® or VitaFlow Liberty® system and are not registered as standalone product in China.

Appendix 2: TAVI Products - Clinical Data Comparison

Company	Product	30-day mortality rate[1]	30-day major (disabling) stroke[1]	1-year mortality rate[1]	1-year major (disabling) stroke[1]	1-year moderate to severe PVL rate	1-year major vascular complications	2-year mortality rate[1]	2-year major (disabling) stroke[1]	3-year mortality rate[1]	3-year major (disabling) stroke[1]	4-year mortality rate	4-year major (disabling) stroke[1]	5-year mortality rate	5-year major (disabling) stroke	6-year mortality rate	6-year major (disabling) stroke	7-year mortality rate	7-year major (disabling) stroke	8-year mortality rate
MicroPort 心通医疗	VitaFlow®	0.9%	0.0%	2.7%	0.0%	0.0%	2.7%	4.6%	0.0%	10.9%	1.8%	12.7%	2.0%	18.2%	2.1%	26.4%	3.4%	32.7%	4.9%	39.1%
	VitaFlow Liberty®	5.0%	0.0%*	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
启明医疗 VENUSMEDTECH	VenusA-Valve	5.0%	1.0%	5.9%	1.0%	4.2%	6.1%	11.6%	N/A	17.4%	N/A	26.7%	N/A	34.1%	N/A	38.2%	N/A	47.7%	N/A	57.0%
	VenusA-Plus	4.8%	1.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JC Medical	J-Valve	4.7%	0.0%	5.6%	2.0%	1.1%	N/A	9.1%	2.0%	10.8%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Medtronic	CoreValve (U.S Pivotal)	3.3%	3.9%	14.2%	5.8%	6.1%	6.2%	22.2%	6.8%	32.9%	8.1%	N/A	N/A	55.3%	12.3%	N/A	N/A	N/A	N/A	N/A
	CoreValve (NOTION low risk)	2.1	N/A	4.9%	N/A	N/A	N/A	8.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	42.5%	N/A	N/A	N/A	N/A
Edwards	SAPIEN 3 (U.S. Trial)	2.2%	0.9%*	14.4%	2.4%*	2.7%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	SAPIEN 3 (China Trial)	0.0%	2.0%*	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	PARTNER-1	N/A	N/A	24.2%	N/A	N/A	11.6%	N/A	N/A	N/A	N/A	N/A	N/A	67.8%	N/A	N/A	N/A	N/A	N/A	N/A
PEIJIA 沛嘉医疗	TaurusOne	1.7%	N/A	6.7%	N/A	1.0%	4.2%	10%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	TaurusElite	2.5%	0.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: [1] The data is from pivotal clinical trial of corresponding products and not head-to-head clinical results. VitaFlow® (N=110), VitaFlow Liberty™ (N=60), VenusA-Valve (N=101), Venus A-Plus (N=62), J-Valve (N=107), TaurusOne (N=120), TaurusElite (N=81), CoreValve (N, TAVI =391), SAPIEN 3 China trial (N=50), U.S. trial (N=583), NOTION (N, TAVI=145), PARTNER-1 (n=348).

*: The data marked with * represent the incidences of disabling stroke

Appendix 3: Product Features - TAVI

Category	Product	Features	Progress
TAVI *5 products* *3 launched*	**VitaFlow Liberty® Flex** 	✦ Improved coaxial release to reduce PVL (Perivalvular leakage) and valve migration risks ✦ Decreased vascular complications ✦ The world's only retrievable steering motorized delivery system with improved stability and precision ✦ Improved usability and safety to prevent excessive release caused by misoperation	✦ **Received NMPA approval in December 2024**
	VitaFlow® IV	✦ Inherit the technical features of VitaFlow® series, such as controllable bending, full retrievability, and strong support ✦ Improvement in terms of profile, durability, and hydrodynamics ✦ Focus on enhancing safety, effectiveness, and usability ✦ To provide patients with both reliable and affordable products	✦ In R&D and design stage
	AR product (In-house development)	✦ Low oversize and low implantation depth reduce pacemaker ✦ Commissure alignment to facilitates coronary artery treatment ✦ Dry tissue for better biocompatibility and anti-calcification properties	✦ In R&D and design stage
Procedural Accessories *2 products launched*	**AccuSniper™ Double-Layer Balloon Catheter**	✦ More stable position during inflation ✦ High burst pressure suits for severe calcification conditions ✦ The world's only double-layer balloon catheter with excellent release stability and puncture resistance	✦ Received NMPA approval in 2023

Note: The above chart is not exhaustive of all our TAVI and procedural accessory products.

Appendix 3: Product Features - TMVR

Category	Product	Features	Progress
TMVR* *2 in FIM*	**TMVR product** (In-house development)	✦ Low profile of stent design reducing LVOTO (Left Ventricular Outflow Tract obstruction) risks ✦ Dry tissue for better biocompatibility and anti-calcification properties ✦ Compatible with both trans-septal or trans-apical approaches	✦ Completed **20+** cases**,** achieved successful at least two-year postoperative follow-up ✦ FIM study
	 **AltaValve** (Partnership with 4C)	✦ Atrial fixation minimizes the risk of LVOT ✦ Supra-annular design with minimal interaction with LV, preserving its structure ✦ Fully recapturable implant prior to final release ✦ Allows treatment of broad patient population covering both DMR and FMR.	✦ **Received breakthrough and IDE approval of FDA** ✦ Gained IDE approval from FDA to conduct a new pivotal study ✦ Initiated a pivotal study in Europe and the US

*Note: * refers to **Transcatheter Mitral Valve Replacement**.*

Appendix 3: Product Features - TTV

Category	Product	Features	Progress
TTVR** *2 in R&D*	**TTVR product (In-house development)**	✦ Minimized postoperative complications due to oversizing by reducing radial support ✦ Effective control of postoperative tricuspid regurgitation ✦ Simplified operation of the delivery system, with better ease of use and low learning curve	✦ In R&D and design stage
	TTVR product (Partnership with 4C)	✦ Supra-annular fit and atrial-only fixation	✦ In R&D and design stage

*Note: ** refers to **Transcatheter Tricuspid Valve Replacement**.*

Appendix 3: Product Features - Left Atrial Appendage Products

Category	Product	Features	Progress
Left Atrial Appendage Products *4products 2 launched 2 in R&D*	**AnchorMan® Left Atrial Appendage Closure (LAAC) System** 	✦ Semi-closed structure formed by the 12 “3D folding” units and the frame: • combines the merits of an open and closed closure device • solves the clinical pain point that the access sheath of the traditional plug-in closure device must deep into the LAA • stable anchoring ✦ Rounded and soft distal end: reduces damage to the LAA tissue ✦ Dense NiTi alloy frame design: allows very tight conformity to the anatomy of LAA and achieves better sealing performance ✦ Two deployment models: advancement and unsheathe, providing more options for physicians	✦ **Received NMPA approval in January 2024** ✦ **Received CE mark in February 2025**
	AnchorMan® Left Atrial Appendage Access (LAAA) System	✦ Compatible with AnchorMan® LAAC System, providing the femoral venous and trans-atrial septal access ✦ Two sizes: single curve and double curve, featuring distinct distal tip configurations for easy navigation into the LAA ✦ The Access Sheath outer diameter and inner diameter are 14 Fr and 12 Fr respectively. The reinforced access sheath has high proximal kink resistance performance. The distal end of access sheath contains 4 radiopaque marker bands for guiding precise placement for AnchorMan® LAAC System.	✦ Received NMPA approval in October 2023 ✦ **Received CE mark in 2024**
	Next generation LAAC & LAAA System	✦ J-shape Anchors design: Improve recovery performance and reduce payout rates ✦ 40mm size added to cover larger left atrial appendage ✦ Dual-stage adjustable bends sheath: Reduce procedure difficulty and avoid re-perforation of the septum. ✦ Anticoagulant coating: Reduce the risk of device thrombosis and to reduce or even avoid the use of postoperative anticoagulants.	✦ In R&D and design stage

Our Mission

To provide trustworthy and universal access to state-of-the-art total solutions to treat structural heart diseases